question 2 of 6\nyour firm can and should respond to the fda-483 during the\ndiscussion with the inspector…

question 2 of 6\nyour firm can and should respond to the fda-483 during the\ndiscussion with the inspector. in fact, corrective actions or\nprocedural changes that were accomplished immediately in the\npresence of the inspector are positive indications of your concern\nand desire to voluntarily correct problems.\n\nq. based on the fda attachment, \what should i expect during an inspection?\, the fda is most likely:\na. interested in assessing the companys ability to comply with regulations.\nb. issuing the fda form 482 to provide the company with compliance actions to take.\nc. sending their representative to teach the company how to manufacture better widgets.\nhint

question 2 of 6\nyour firm can and should respond to the fda-483 during the\ndiscussion with the inspector. in fact, corrective actions or\nprocedural changes that were accomplished immediately in the\npresence of the inspector are positive indications of your concern\nand desire to voluntarily correct problems.\n\nq. based on the fda attachment, \what should i expect during an inspection?\, the fda is most likely:\na. interested in assessing the companys ability to comply with regulations.\nb. issuing the fda form 482 to provide the company with compliance actions to take.\nc. sending their representative to teach the company how to manufacture better widgets.\nhint

Answer

Brief Explanations:

The FDA's inspection focus, as referenced, centers on evaluating a firm's adherence to regulatory standards. Corrective actions during inspection demonstrate the firm's compliance capacity, aligning with the FDA's core goal of assessing regulatory compliance. Option B is incorrect because FDA 483 lists observations, not required compliance actions. Option C is incorrect as the FDA does not inspect to teach manufacturing practices for specific products like widgets.

Answer:

A. interested in assessing the company's ability to comply with regulations.